Mktropin (MK677)
Mktropin is a clinically proven supplement that will increase your GH production, making it a better option for those who want the same benefits of using GH without the discomfort of applications, side effects and high costs.
Mktropin was developed to treat people who have low levels of IGF-1. One of the growth factors best known for its ability to promote increased muscle mass is IGF-1. Its other role is aimed at people with low levels of GH (growth hormone), as IGF-1 also helps stimulate GH.
It also stimulates anabolic pathways within cells, thereby increasing protein synthesis and inhibiting Myostatin production.
This combination of effects helps to increase lean muscle mass, reduce adipose tissue mass and improve bone density.
Benefits:
- Significantly increases lean body mass;
- Reduces the mass of adipose tissue;
- Improves bone density;
- Improves sleep quality;
- Reduced inflammation;
- Enhanced cognitive function;
- Increased muscle strength;
- Improved cardiovascular health;
- Increased GH levels;
- Increased levels of IGF-1.
Contraindication:
Individuals who have:
- Low or high blood pressure;
- Heart problems;
- Complications in the heart, liver or kidneys;
- Thyroid problems;
- Psychophysiological complications;
- Diabetes;
- Users of MAO-B inhibitors, MAOIs, SSRIs or antidepressants.
Collateral effects
- By using the product correctly and following the recommended dosage, the side effects are practically zero;
- There are no studies that say there are side effects to the use of Mktropin.
Usage recommendation:
- Men: 1 to 2 Capsules a day;
- Women: 1 Capsule a day;
- Do not exceed the recommended dosage;
- It can be used over a period of 4 to 12 weeks, when you finish using it, take a 4-week break to be able to use the product again and enjoy better results.
It is extremely important that when using Mktropin, you follow a suitable diet and high-intensity training in order to take full advantage of the product.
Keep the product in a dry and ventilated place.
Reviews
There are no reviews yet.